-+ 0.00%
-+ 0.00%
-+ 0.00%

Samsung EPIS Holdings Says Bioepis Secures Exclusive Brazil Supply Deal for Rare Disease Drug

PUBT·11/20/2026 07:45:09
Listen to the news
Samsung EPIS Holdings Says Bioepis Secures Exclusive Brazil Supply Deal for Rare Disease Drug
  • Samsung EPIS Holdings confirmed subsidiary Samsung Bioepis signed an exclusive supply agreement for rare-disease treatment SB12 under Brazil’s government-led Productive Development Partnership.
  • SB12 is an eculizumab biosimilar of Soliris.
  • The clarification addresses Oct. 21, 2026, media reports of a 10-year exclusive supply deal in Brazil.
  • Additional supply contracts are planned to implement the agreement; quantities and unit prices remain undecided.
  • A further disclosure is scheduled by Feb. 19, 2027, or earlier if finalized supply terms trigger disclosure requirements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261120800677), on November 20, 2026, and is solely responsible for the information contained therein.